Comparison of efficacy and price between tenofovir alafenamide tablets (Vemlidy) and entecavir

Tenofovir alafenamide fumarate tablets (Vemlidy) and entecavir (Entecavir) are both antiviral drugs for the treatment of chronic hepatitis B, but they are different types of nucleoside (acid) inhibitors. Tenofovir alafenamide tablets are a prodrug form of tenofovir that inhibits hepatitis B virus (HBV) polymerase and blocks viral DNA synthesis, thereby inhibiting viral replication. Entecavir is a deoxyadenosine nucleoside analog that also works by inhibiting HBV DNA polymerase. Both can effectively reduce serum HBV DNA levels, but the pharmacokinetics of tenofovir alafenamide fumarate tablets are optimized so that the daily dosage is low and the burden on the kidneys is less.

In clinical studies, both tenofovir alafenamide tablets and entecavir have shown the ability to effectively inhibit HBV DNA replication. For patients with limited treatment experience, there is not much difference between the two in terms of virological response rate and ALT recovery rate. However, in special groups (such as mild to moderate renal insufficiency or elderly patients), tenofovir alafenamide tablets have a better safety profile due to their stable drug concentration and low renal toxicity. In addition, long-term use of both drugs can significantly reduce the risk of cirrhosis and liver cancer, but tenofovir alafenamide fumarate tablets may be slightly better in terms of bone and renal function protection.

In terms of price, the difference is significant. Tenofovir alafenamide fumarate tablets have been launched in China and are included in medical insurance. The price of 25mg*30 tablets is about more than 300 yuan. The price of generic drugs overseas in India and Laos is 100 to 200 yuan, and the drug ingredients are basically the same as the original drugs. In comparison, the domestic price of entecavir is very low. Each tablet can be purchased for just a few yuan, and the cost of long-term medication is significantly lower. Therefore, entecavir is still the first choice for patients with greater financial pressure; while for patients with special needs for kidney or bone health, tenofovir alafenamide tablets provide better safety.

Generally speaking, both drugs are relatively reliable in antiviral efficacy, and clinical selection is more based on the patient's individual situation and economic factors. If the patient pursues low cost and has normal renal function, entecavir is still a cost-effective choice; if the patient has long-term medication needs, renal function or bone density risks, tenofovir alafenamide fumarate tablets have obvious advantages. In addition, medical insurance coverage and the existence of overseas generic drugs also provide patients with flexible access channels. Clinical recommendations are based on Comprehensive assessment of viral load, renal function, bone density and financial affordability The medication regimen should be adjusted individually.

Reference link:https://www.drugs.com